Cosmetic or pharmaceutical formulation
The present invention relates to a cosmetic or pharmaceutical formulation comprising a hyaluronate crosspolymer and one or more of (a) azelaic acid or an ester thereof; (b) one or more of black cumin seed oil, chaulmoogra oil, magnolia bark extract and manuka oil; and (c) resveratrol or a derivative thereof. Uses of the formulation for skin treatments, promoting collagen production and regulating cellular turnover are also described.
1. A cosmetic or pharmaceutical formulation for treating or preventing one or more of a condition involving blocked sebaceous glands, an inflammatory skin condition, a microbial skin infection, dermal oxidation damage and pigmentation, the formulation comprising:
(i) a hyaluronate crosspolymer or a salt thereof in an amount of 0.05% to 4% w/w; and
(ii) 0.2% to 4% w/w of a mixture consisting of comprising black cumin seed oil, chaulmoogra oil, magnolia bark extract and Manuka oil.
2. The formulation of claim 1 , further comprising one or more of:
(a) azelaic acid or a salt or ester thereof; and
(b) resveratrol or a derivative thereof.
3. The formulation of claim 2 , comprising:
(a) azelaic acid or a salt or ester thereof; and
(b) resveratrol or a derivative thereof.
4. The formulation of claim 1 , wherein the formulation comprises the hyaluronate crosspolymer or a salt thereof in an amount of 0.1 to 2% w/w.
5. The formulation of claim 1 , wherein the mixture includes one or more of thymoquinone, 5′-methoxyhydnocarpin, hydnocarpic acid, chaulmoogric acid, gorlic acid, honokiol, magnolol, flavesone, leptospermone and isoleptospermone.
6. The formulation of claim 2 , wherein the azelaic acid or a salt or ester thereof is a mono- or di-ester of azelaic acid with an amino acid or a salt thereof.
7. The formulation of claim 6 , wherein the mono- or di-ester of azelaic acid is azeloyl diglycinate or a salt thereof.
8. The formulation of claim 2 , wherein the formulation comprises azelaic acid or a salt or ester thereof in an amount of less than 5% w/w.
9. The formulation of claim 2 , wherein the resveratrol or a derivative thereof is a derivative of resveratrol.
10. The formulation of claim 9 , wherein the derivative of resveratrol is a product from an enzymatic treatment of resveratrol.
11. The formulation of claim 10 , wherein the derivative of resveratrol is an extract produced by fermentation of resveratrol.
12. The formulation of claim 2 , wherein the formulation comprises resveratrol or a derivative thereof in an amount of less than 5% w/w.
13. The formulation of claim 1 , wherein the formulation further includes one or more agents that stimulate collagen production.
14. The formulation of claim 13 , wherein the one or more agents that stimulate collagen production are selected from one or more of: a retinoid, an isoflavone or a substituted derivative thereof and salicylic acid or a salt or derivative thereof.
15. The formulation of claim 1 , wherein the formulation further comprises one or more antioxidants.
16. The formulation of claim 15 , wherein the one or more antioxidants are selected from: ascorbic acid or a salt or derivative thereof, tocopherol or a derivative thereof, ubiquinone or a derivative thereof, lactobionic acid or a salt or derivative thereof, gluconolactone or a derivative thereof and maltobionic acid or a salt or derivative thereof.
17. A method of treating or preventing one or more of a condition involving blocked sebaceous glands, an inflammatory skin condition, a microbial skin infection, dermal oxidation damage and pigmentation, comprising administering to a subject in need thereof an effective amount of the formulation of claim 1 .
18. The method of claim 17 , wherein the microbial skin infection is a bacterial infection.
19. A method of promoting collagen production in a dermal matrix or regulating cellular turnover, comprising administering to a subject in need thereof an effective amount of the formulation of claim 1 .